Inclisiran, Low-Density Lipoprotein Cholesterol and Lipoprotein (a)

Dyslipidemia treatment is of major importance in reducing the risk of atherosclerotic cardiovascular disease (ASCVD), which is still the most common cause of death worldwide. During the last decade, a novel lipid-lowering drug category has emerged, i.e., proprotein convertase subtilisin/kexin type 9...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsiki, Niki, Vrablik, Michal, Banach, Maciej, Gouni-Berthold, Ioanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143414/
https://www.ncbi.nlm.nih.gov/pubmed/37111334
http://dx.doi.org/10.3390/ph16040577

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143414/
https://www.ncbi.nlm.nih.gov/pubmed/37111334
http://dx.doi.org/10.3390/ph16040577

Ejemplares similares